Clinical Follow-Up of Prostatic Cancer Patients under Intermittent Treatment with Fosfestrol and Bromocriptine

Abstract

A clinical follow-up is presented of 152 patients with newly diagnosed prostatic cancer, confirmed histopathologically and intermittently treated with Fosfestrol and bromocriptine in the last few years. The optimal dosage of Fosfestrol and bromocriptine was established on the basis of serum testosterone and prolactin levels. The reduction of Fosfestrol dosage combined with bromocriptine and the intermittent administration of estrogens resulted in a prolongation of the period of sensitivity to female hormones, in a better tolerance for the drugs, and in a reduced number of side effects.

Development and Clinical Application of Phosphorus-Containing Drugs

“…For example, fosfestrol sodium* ( 15 ) is an estrogen receptor (ER) agonist in prostatic cancer therapy and this drug is derived from the phosphorylation of hormone drug fosdestrol* (Distilbene/Stilbestrol/Stilbetin®) ( 14 ). Fosfosal (Aydolid/Disdolen®) ( 16 ) is a salicylic acid phosphate serving as a nonsteroidal anti-inflammatory and analgesic drug (NSAID) [ 37 ]. As a topoisomerase (DNA) II alpha (TOP2A) inhibitor, etoposide phosphate (Etopophos®1996, 17 ) exhibits sufficient aqueous solubility to minimize the probability of drug precipitation by injection, which is widely used for treating testicular cancer, small cell lung cancer, multiple myeloma, acute lymphoblastic leukemia, and non-Hodgkin’s lymphoma [ 5 , [38] , [39] , [40] ].…”